Your browser doesn't support javascript.
Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19.
Sokolowska, Milena; Rovati, G Enrico; Diamant, Zuzana; Untersmayr, Eva; Schwarze, Jürgen; Lukasik, Zuzanna; Sava, Florentina; Angelina, Alba; Palomares, Oscar; Akdis, Cezmi A; O'Mahony, Liam; Jesenak, Milos; Pfaar, Oliver; Torres, María José; Sanak, Marek; Dahlén, Sven-Erik; Woszczek, Grzegorz.
  • Sokolowska M; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
  • Rovati GE; Christine Kühne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.
  • Diamant Z; Department of Pharmaceutical Sciences, Section of Pharmacology and Biosciences, University of Milan, Milano, Italy.
  • Untersmayr E; Department of Respiratory Medicine and Allergology, Skane University Hospital, Lund, Sweden.
  • Schwarze J; Department Microbiology Immunology and Transplantation, Ku Leuven, Catholic University of Leuven, Belgium.
  • Lukasik Z; Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
  • Sava F; Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
  • Angelina A; Child Life and Health and Centre for Inflammation Research, The University of Edinburgh, Edinburgh, UK.
  • Palomares O; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
  • Akdis CA; VIB Center for Inflammation Research, Ghent University, Ghent, Belgium.
  • O'Mahony L; London North Genomic Laboratory Hub, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.
  • Jesenak M; Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.
  • Pfaar O; Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.
  • Torres MJ; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
  • Sanak M; Christine Kühne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.
  • Dahlén SE; Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.
  • Woszczek G; Department of Pulmonology and Phthisiology, Department of Allergology and Clinical Immunology, Department of Pediatrics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Teaching Hospital in Martin, Slovakia.
Allergy ; 77(8): 2337-2354, 2022 08.
Article in English | MEDLINE | ID: covidwho-1691634
ABSTRACT
Non-steroidal anti-inflammatory drugs (NSAIDs) and other eicosanoid pathway modifiers are among the most ubiquitously used medications in the general population. Their broad anti-inflammatory, antipyretic, and analgesic effects are applied against symptoms of respiratory infections, including SARS-CoV-2, as well as in other acute and chronic inflammatory diseases that often coexist with allergy and asthma. However, the current pandemic of COVID-19 also revealed the gaps in our understanding of their mechanism of action, selectivity, and interactions not only during viral infections and inflammation, but also in asthma exacerbations, uncontrolled allergic inflammation, and NSAIDs-exacerbated respiratory disease (NERD). In this context, the consensus report summarizes currently available knowledge, novel discoveries, and controversies regarding the use of NSAIDs in COVID-19, and the role of NSAIDs in asthma and viral asthma exacerbations. We also describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to predict responses to LTRA therapy and discuss a potential role of LTRA therapy in COVID-19 treatment. Moreover, we discuss interactions of novel T2 biologicals and other eicosanoid pathway modifiers on the horizon, such as prostaglandin D2 antagonists and cannabinoids, with eicosanoid pathways, in context of viral infections and exacerbations of asthma and allergic diseases. Finally, we identify and summarize the major knowledge gaps and unmet needs in current eicosanoid research.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Asthma / COVID-19 Drug Treatment / Hypersensitivity Type of study: Experimental Studies / Prognostic study Limits: Humans Language: English Journal: Allergy Year: 2022 Document Type: Article Affiliation country: All.15258

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Asthma / COVID-19 Drug Treatment / Hypersensitivity Type of study: Experimental Studies / Prognostic study Limits: Humans Language: English Journal: Allergy Year: 2022 Document Type: Article Affiliation country: All.15258